DK1789053T3 - Fremgangsmåde til sårheling under anvendelse af a2b-adenosinreceptor-antagonister - Google Patents

Fremgangsmåde til sårheling under anvendelse af a2b-adenosinreceptor-antagonister

Info

Publication number
DK1789053T3
DK1789053T3 DK05811901.7T DK05811901T DK1789053T3 DK 1789053 T3 DK1789053 T3 DK 1789053T3 DK 05811901 T DK05811901 T DK 05811901T DK 1789053 T3 DK1789053 T3 DK 1789053T3
Authority
DK
Denmark
Prior art keywords
procedure
health care
receptor antagonists
adenosin
adenosin receptor
Prior art date
Application number
DK05811901.7T
Other languages
Danish (da)
English (en)
Inventor
Dewan Zeng
Luiz Belardinelli
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK1789053T3 publication Critical patent/DK1789053T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK05811901.7T 2004-09-01 2005-08-30 Fremgangsmåde til sårheling under anvendelse af a2b-adenosinreceptor-antagonister DK1789053T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
DK1789053T3 true DK1789053T3 (da) 2012-08-06

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05811901.7T DK1789053T3 (da) 2004-09-01 2005-08-30 Fremgangsmåde til sårheling under anvendelse af a2b-adenosinreceptor-antagonister

Country Status (21)

Country Link
US (1) US20060058322A1 (enExample)
EP (1) EP1789053B1 (enExample)
JP (2) JP4929173B2 (enExample)
KR (1) KR101247528B1 (enExample)
CN (1) CN101043889B (enExample)
AU (1) AU2005282860B2 (enExample)
CA (1) CA2578702A1 (enExample)
DK (1) DK1789053T3 (enExample)
ES (1) ES2387653T3 (enExample)
HR (1) HRP20120712T1 (enExample)
IL (1) IL181634A (enExample)
MX (1) MX2007002437A (enExample)
NO (1) NO20071718L (enExample)
NZ (1) NZ553487A (enExample)
PL (1) PL1789053T3 (enExample)
PT (1) PT1789053E (enExample)
RS (1) RS52455B (enExample)
RU (1) RU2385322C2 (enExample)
SI (1) SI1789053T1 (enExample)
WO (1) WO2006028810A2 (enExample)
ZA (1) ZA200701777B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4769721B2 (ja) * 2003-08-25 2011-09-07 トロヴィス ファーマシューティカルズ リミテッド ライアビリティ カンパニー 置換８−ヘテロアリールキサンチン
RU2391103C2 (ru) 2004-10-15 2010-06-10 Си Ви Терапьютикс, Инк. Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
WO2006091936A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
US20210040097A1 (en) * 2018-03-05 2021-02-11 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
JP2023540740A (ja) * 2020-09-04 2023-09-26 テオン セラピューティクス，インク． アデノシンａ２ｂ受容体アンタゴニストの共結晶

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
AU6516494A (en) * 1993-04-15 1994-11-08 New York University Adenosine receptor agonists for the promotion of wound healing
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
JP2003535818A (ja) * 2000-02-17 2003-12-02 スィーヴィー セラピューティクス インコーポレイテッド 哺乳動物細胞増殖を媒介するａ２ｂアデノシンリセプタ拮抗剤の同定および使用方法
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
PT1444233E (pt) * 2001-11-09 2011-09-29 Gilead Palo Alto Inc Antagonistas de receptor de adenosina a2b
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
DE602004018808D1 (de) * 2003-10-31 2009-02-12 Cv Therapeutics Inc Antagonisten des a2b-adenosinrezeptors

Also Published As

Publication number Publication date
JP2011246492A (ja) 2011-12-08
CN101043889A (zh) 2007-09-26
CN101043889B (zh) 2010-11-03
IL181634A0 (en) 2007-07-04
RU2385322C2 (ru) 2010-03-27
PL1789053T3 (pl) 2012-12-31
WO2006028810A3 (en) 2006-09-28
KR101247528B1 (ko) 2013-04-15
MX2007002437A (es) 2007-08-14
JP2008511654A (ja) 2008-04-17
RU2007107605A (ru) 2008-09-10
WO2006028810A2 (en) 2006-03-16
KR20070047816A (ko) 2007-05-07
SI1789053T1 (sl) 2012-09-28
ES2387653T3 (es) 2012-09-27
CA2578702A1 (en) 2006-03-16
HRP20120712T1 (hr) 2012-10-31
AU2005282860A1 (en) 2006-03-16
EP1789053A2 (en) 2007-05-30
PT1789053E (pt) 2012-08-09
NZ553487A (en) 2010-09-30
RS52455B (sr) 2013-02-28
HK1107261A1 (en) 2008-04-03
JP4929173B2 (ja) 2012-05-09
US20060058322A1 (en) 2006-03-16
ZA200701777B (en) 2008-09-25
AU2005282860B2 (en) 2012-03-22
IL181634A (en) 2015-05-31
EP1789053B1 (en) 2012-06-13
NO20071718L (no) 2007-03-30

Similar Documents

Publication Publication Date Title
ATE452886T1 (de) Chemokinrezeptorantagonisten
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
DE602004030930D1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
DK1750640T3 (da) Anordning til patientforflytning med skrånende øvre overflade
DK1951660T3 (da) Histamin-3-receptorantagonister
DE602005018568D1 (de) Bildschirmhalterungsvorrichtung
ATE413400T1 (de) Cgrp-rezeptorantagonisten
PT1857457E (pt) Derivado de benzimidazole e sua utilização como antagonista do receptor a ii
DK2081951T3 (da) Progesteron-receptorantagonister
DK1827104T3 (da) Fremgangsmåder til at fremme dyrs orale sundhed
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
DK1844070T3 (da) Peptider med neuropeptid-2 receptor (Y2R) agonistaktivitet
DE502005004847D1 (de) Prothesenvorrichtung
EP1765805A4 (en) CGRP RECEPTOR ANTAGONISTS
DK1761519T3 (da) Indolderivater som histaminreceptorantagonister
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DK1789053T3 (da) Fremgangsmåde til sårheling under anvendelse af a2b-adenosinreceptor-antagonister
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada
ATE534628T1 (de) Urotensin ii-rezeptorantagonisten
EP1799672A4 (en) CGRP RECEPTOR ANTAGONIST
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
EP1954268A4 (en) SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS
EP1819342A4 (en) QUINOLINE tachykinin ANTAGONISTS
FI20060188L (fi) Modifioidut IL-4-muteiinin reseptorin antagonistit